소 결핵 진단 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2024-2032년)

The Global Bovine Tuberculosis Diagnosis Market reached USD 795.5 million in 2023 and is projected to expand at 7.5% CAGR from 2024 to 2032. This growth is largely driven by the increasing prevalence of bovine tuberculosis worldwide and significant innovations in diagnostic technology.

Strict government regulations and proactive initiatives are key drivers for the market, with authorities worldwide implementing more rigorous testing protocols to curb the spread of bovine tuberculosis. Furthermore, the rising consumption of dairy products is boosting the demand for healthier cattle populations, making comprehensive bovine tuberculosis diagnostics essential for safeguarding public health.

The market is divided into two main categories: products and services. The product segment holds the largest share and is expected to grow at a CAGR of 7.4% during the forecast period. This dominance is attributed to a wide range of diagnostic tools, such as PCR assays, tuberculin skin tests, and ELISA kits. Continuous research and development efforts are enhancing the effectiveness of these tools. Moreover, innovations in point-of-care testing and the integration of automation in diagnostic laboratories are further accelerating growth in this segment.

The market is also segmented by sample type, which includes blood, nasal swabs, tissue samples, and others. Blood samples held the largest market share at 55.4% in 2023. This dominance is due to the effectiveness of blood samples in detecting Mycobacterium bovis, the causative agent of bovine tuberculosis. Serological tests, which examine blood for specific antibodies or antigens, provide reliable and quick results, making them the preferred method for early detection and timely intervention. The non-invasive nature of blood sampling, combined with its simplicity, also contributes to its widespread use in routine surveillance and testing programs.

The U.S. bovine tuberculosis diagnosis industry is expected to grow at a CAGR of 6.9% from 2024-2032. The growth in this market is driven by advancements in diagnostic techniques and enhanced surveillance capabilities. The introduction of molecular testing methods, such as PCR and next-generation sequencing, has improved diagnostic accuracy and efficiency in detecting tuberculosis in livestock. The adoption of advanced diagnostic tools and comprehensive screening programs has made it easier to detect the disease early, ensuring better control and management of outbreaks. These technological advancements and strengthened surveillance practices position the U.S. as a key player in the global bovine tuberculosis diagnosis market.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of bovine tuberculosis
    • 3.2.1.2 Research and development in diagnostic techniques
    • 3.2.1.3 Government support and initiatives
    • 3.2.1.4 Increasing consumption of dairy products
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Lack of standardized diagnostic protocols
• 3.3 Growth potential analysis
• 3.4 Future market trends
• 3.5 Technology landscape
• 3.6 Regulatory landscape
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Product
• 5.3 Services
  • 5.3.1 Tuberculin skin test
    • 5.3.1.1 Comparative Cervical Test (CCT)
    • 5.3.1.2 Single Intradermal Test (SIT)
    • 5.3.1.3 Single Cervical Test (SCT) or Caudal (tail) Fold Test (CFT)
  • 5.3.2 Blood-based assay test
    • 5.3.2.1 Gamma Interferon (IFN-Y) assay
    • 5.3.2.2 Enzyme-linked Immunosorbent Assay (ELISA)
    • 5.3.2.3 Other blood-based assay test
  • 5.3.3 Molecular diagnostics tests

Chapter 6 Market Estimates and Forecast, By Sample Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Blood sample
• 6.3 Nasal swabs
• 6.4 Tissue sample
• 6.5 Other samples

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Veterinary hospitals
• 7.3 Research institutes
• 7.4 Veterinary diagnostic laboratories
• 7.5 Livestock farms and ranches

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Bio-Rad Laboratories
• 9.2 Chembio Diagnostics
• 9.3 Enfer
• 9.4 IDEXX Laboratories
• 9.5 IDVet
• 9.6 LIONEX
• 9.7 PBD Biotech
• 9.8 QIAGEN
• 9.9 Thermo Fisher Scientific
• 9.10 ZENDAL